Can-Fite BioPharma Ltd.
10 Bareket Street
Kiryat Matalon Petah Tikva, 4951778, Israel
Phone: 972 3 924 1114
http://www.canfite.com

Company Overview: Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company.

- **Novel therapeutic approach –** unique technology for the treatment of liver and inflammatory diseases; addressing multi-billion dollar markets
- **Oral drugs with proven safety and efficacy** - Piclidenoson and Namodenoson are Phase III assets in psoriasis and liver cancer; Namodenoson showed strong efficacy in a Phase II NASH study; Piclidenoson is approved by FDA and IRBs to commence Phase II study in patients with moderate COVID-19
- **Intellectual property portfolio -** consists of 15 patent families issued and pending to protect different indications
- **Corporate partnerships -** Piclidenoson and Namodenoson have been out-licensed in select territories with ~$18 million received to date
- **Financially well positioned –** the Company is well positioned to conduct all its clinical development programs and G&A for > 1 year

Equity Overview (as of January 2021)

NYSE American: CANF
TASE: CFBI
1 ADR = 30 ordinary TASE shares
ADRs Outstanding: ~15.4 M
Ordinary Shares Outstanding: ~462 M

Analyst Coverage

H.C. Wainwright
Dawson James

Platform Technology

- Small molecule
- Orally bioavailable
- Anti-inflammatory and anti-cancer effects
- Excellent safete profile in over 1,500 pateints

Targeting the A3 Adenosine Receptor (A3AR)



Out-licensing Deals: $18 M Received to Date Typical Deal Structure

- Up-front money upon signing a distribution deal
- Regulatory milestone payments
- Sales milestone payments
- Royalties (double-digit)

**Sources for market size estimates: SNS Research, DelveInsight, Deutsche Bank, Adroit Market Research*

Investor Contact:

Motti Farbstein, CFO, + 972 3 924 1114

Disclaimer: Except for historical information contained herein, the statements in this fact sheet are "forward looking" within the meaning of the Private Securities Litigation Act of 1995. This fact sheet includes estimates and projections and, as such, reflects only management's current expectations. A fuller discussion of Can-Fite BioPharma Ltd's risks and uncertainties are described in the Company's filings with the Securities and Exchange Commission, which should be reviewed in conjunction with this overview.

Drug Development Pipeline



Platform Technology - Targeted Therapy

Can-Fite's platform technology is based on the finding that the Gi protein-coupled A3 adenosine receptor (A3AR) is over-expressed in inflammatory and cancer cells. The Company's proprietary compounds target and bind with A3AR and induce specific cell death of cancer and inflammatory cells. This creates a targeted anti-cancer and anti-inflammatory effect, while leaving normal cells unharmed.

Piclidenoson Clinical Development

- **Phase III Psoriasis – Positive Interim Analysis Data Reported**

  Can-Fite has completed enrollment of over 50% of the expected ~ 400 patients with moderate-to-severe psoriasis in its pivotal Phase III Comfort trial. The trial is designed to establish superiority vs. placebo and non-inferiority vs. Otezla®. Based on recent positive results from an interim data analysis, Can-Fite continues to enroll and treat patients.

- **Phase II COVID-19 – Enrollment to Commence Q1 2021**

  As an anti-inflammatory and anti-viral drug, Piclidenoson has the potential to treat COVID-19. The FDA has cleared Can-Fite to commence enrollment of 40 patients in a 28-day Phase II study of Piclidenoson as a potential addition to standard of care in COVID-19 infected patients with moderate symptoms.

Namodenoson Clinical Development

- **Pivotal Phase III Study in Liver Cancer – Under Preparation**

  Can-Fite received agreement from both the FDA and European Medicines Agency (EMA) for a pivotal Phase III study for market registration. Namodenoson has Orphan Drug status with both FDA and EMA, as well as Fast Track Status with the FDA.

- **Phase II NASH Study Showed Efficacy – Phase IIb Under Preparation**

  Namodenoson's Phase II NASH/NAFLD study met all efficacy and safety endpoints including anti-inflammatory effects and reduced liver fat content. Can-Fite is now preparing a Phase IIb study in NASH, with manufacturing of the drug supply complete. NASH is an unmet medical need projected to become a $35-$40 billion market by 2025.